PDL BioPharma, Inc. PDLIV
NASDAQ
Recommendation
Dividend Power Score
Day's Range
Latest Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
--
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
--
| 08/31/2020 | 06/30/2020 | 03/31/2020 | |||
|---|---|---|---|---|---|
| Revenue | -- | 5.21M | 6.00M | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | 5.21M | 6.00M | ||
| Cost of Revenue | -- | 2.64M | 2.86M | ||
| Gross Profit | -- | 2.57M | 3.14M | ||
| SG&A Expenses | -- | 10.96M | 14.12M | ||
| Depreciation & Amortization | -- | 335.00K | 302.00K | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | -- | 15.40M | 19.14M | ||
| Operating Income | -- | -10.18M | -13.14M | ||
| Income Before Tax | -- | -14.01M | -46.24M | ||
| Income Tax Expenses | -- | -1.08M | -14.47M | ||
| Earnings from Continuing Operations | -- | -12.93M | -31.77M | ||
| Earnings from Discontinued Operations | -- | -37.40M | -244.00K | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | 357.00K | 288.00K | ||
| Net Income | -- | -49.97M | -31.72M | ||
| EBIT | -- | -10.18M | -13.14M | ||
| EBITDA | -- | -9.49M | -12.33M | ||
| EPS Basic | -- | -0.43 | -0.26 | ||
| Normalized Basic EPS | -- | -0.05 | -0.06 | ||
| EPS Diluted | -- | -0.43 | -0.26 | ||
| Normalized Diluted EPS | -- | -0.05 | -0.06 | ||
| Average Basic Shares Outstanding | -- | 115.91M | 122.90M | ||
| Average Diluted Shares Outstanding | -- | 115.91M | 122.90M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||